Long-term safety follow-up of people treated with cilta-cel for multiple myeloma
Follows adults with multiple myeloma previously treated with cilta-cel to study late side effects.
Plain-language title generated from the registry record
Registry title: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Key facts
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca, and Sevilla, SpainSee the 7 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received at least one dose of cilta-cel in a Company-sponsored clinical study. It follows them over the long term to check for late side effects.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- Must have received at least one dose of cilta-cel in a Company-sponsored clinical study.
Read by machine on 11 November 2026.
Where in Spain
- Institut Catala d'OncologiaBadalona, SpainTaking people
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
- Hospital General Universitario Gregorio MarañónMadrid, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
- Hospital Universitario De SalamancaSalamanca, SpainTaking people
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT05201781EU 2023-505530-10-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.Read full original descriptionShow less
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Inclusion: Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study; Participants who have provided informed consent for this study.